Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver

Simple item page
dc.contributor.authorGonzalezMartin, G
dc.contributor.authorDominguez, AR
dc.contributor.authorGuevara, A
dc.date.accessioned2024-01-10T12:41:23Z
dc.date.available2024-01-10T12:41:23Z
dc.date.issued1997
dc.description.abstractPharmacokinetics and hepatotoxicity of diclofenac was studied in a recirculating model of isolated perfused rat liver. Ten male Sprague-Dawley rat (weighing 230-330 g) livers were perfused for 2 h with 250 mt Krebs-Henseleit bicarbonate buffer that contained 10.75 mg (group A, a = 5) and 1.075 mg (group B, n = 5) of diclofenac (approximately 100 and 10 times the therapeutic dose in man, respectively). Samples were collected from the efflux at regular time intervals for the determination of diclofenac concentrations by a high performance liquid chromatography (HPLC) method. Pharmacokinetic analyses were carried out using a computer program. To establish viability of the liver and toxicity of the drug, enzyme activity measurements of lactate dehydrogenase (LDH), aspartate aminotransferase (SGOT) and piruvate aminotransferase (SGPT) were performed by a spectrophotometric method. Oxygen consumption was also recorded during the entire perfusion period. Both groups presented bicompartmental kinetics. Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mt min(-1) g(-1) liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life. a 0.1164 +/- 0.067 mt min(-1) g(-1) liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002). LDH activity showed a significant increase in group A at 90 min in comparison with the control group, while in group B this increase was significantly higher at 10 min (P < 0.004). The aminotransferase levels did not show a significant increase. According to these results, diclofenac would not have a direct hepatotoxic effect, even at doses 100 times higher than therapeutic ones.
dc.fechaingreso.objetodigital2024-04-11
dc.format.extent6 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/S0753-3322(97)85586-2
dc.identifier.issn0753-3322
dc.identifier.pubmedidMEDLINE:9207985
dc.identifier.urihttps://doi.org/10.1016/S0753-3322(97)85586-2
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77411
dc.identifier.wosidWOS:A1997WZ97700006
dc.information.autorucQuímica;González G;S/I;98524
dc.issue.numero4
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final175
dc.pagina.inicio170
dc.publisherEDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.revistaBIOMEDICINE & PHARMACOTHERAPY
dc.rightsacceso restringido
dc.subjectdiclofenac
dc.subjecthepatotoxicity
dc.subjectperfused rat liver
dc.subjectHEPATITIS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver
dc.typeartículo
dc.volumen51
sipa.codpersvinculados98524
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver.pdf
Size:
3.22 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas